Please assess the completion status of the following clinical trial:

Trial Title: Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Waldenstrom's macroglobulinemia (WM) or marginal zone lymphoma (MZL) based on institutional pathology review; patients may have either previously untreated or relapsed/refractory disease~* Measurable disease: for WM presence of monoclonal IgM immunoglobulin concentration on serum electrophoresis, with lymphoplasmacytic marrow infiltrate; for MZL: measurable nodal disease measuring at least 1.5 cm in longest dimension, or splenomegaly~* Indication for initiation of therapy~* Absolute neutrophil count (ANC) \> 1,000/uL unless disease-related (due to marrow infiltration or splenomegaly)~* Platelet count \> 75,000/uL unless disease-related (due to marrow infiltration or splenomegaly)~* Serum creatinine \< 2.5 mg/dL or creatinine clearance \> 30 cc/min~* Bilirubin \< 2 x upper limit of normal (ULN)~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x ULN~* All patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines~* Expected survival of \> 90 days~* Females of childbearing potential (FCBP) must agree to pregnancy testing and to practice contraception~* Male subjects must agree to practice contraception~Exclusion Criteria:~* Known human immunodeficiency virus (HIV), hepatitis C, or hepatitis B positivity (subjects with hepatitis B surface antigen \[SAg\] or core antibody positivity, who are receiving and responding to antiviral therapy directed at hepatitis B or are negative for hepatitis B virus \[HBV\] deoxyribonucleic acid \[DNA\], are allowed)~* Candidate for potentially curative antibiotic therapy for gastric mucosa-associated lymphoid tissue (MALT); (gastric MALT lymphoma patients with stage I/II helicobacter \[H.\] pylori positive lymphoma must fail therapy with H.-pylori directed therapy before being considered for this study)~* Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher~* Known active central nervous system (CNS) involvement~* Pregnant or lactating females~* Inadequate cardiac function, as measured by left ventricular ejection fraction (LVEF) that is less than or equal to 40%, or the presence of New York Heart Association (NYHA) classification of greater than stage II congestive heart failure~* Significant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to screening~* Uncontrolled inter-current illness including, but not limited to, unstable angina, recent myocardial infarction within 6 months of screening and uncontrolled cardiac arrhythmias, psychiatric illness, or psychosocial difficulty that would limit compliance with study requirements~* Non-hematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (carfilzomib, rituximab) (Type: EXPERIMENTAL): Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve at least 25% M-protein reduction for Waldenstrom's macroglobulinemia or partial response for marginal zone lymphoma after 2 courses of carfilzomib, receive rituximab IV weekly on days 1, 8, 15, and 22 of course 3 and then monthly on day 1 of courses 4-6 in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).